Why China’s Clinical Development Ecosystem Is Becoming Harder to Ignore

Had a great conversation recently with Betty Bian from Tigermed about how China’s clinical development ecosystem is evolving, and what this means for global biotech companies.

One of the biggest takeaways was that China’s clinical development speed is not simply about having access to large patient populations. That is only one part of the story. Increasingly, the speed comes from a combination of regulatory reform, faster site start-up, concentrated patient pools, and highly experienced investigators at major hospitals.

We also discussed why many biotech programs begin with investigator-initiated trials, or IITs, in China.

A well-designed IIT can be a powerful way to generate early human data, test biomarker or mechanism hypotheses, and identify strong clinical sites and investigators before moving into more formal IND-enabling development. However, IITs should not be viewed as a substitute for registrational studies. Their value depends heavily on the quality of study design, operational execution, and how well the data can support the next stage of development.

Another important point was timing. For international biotech companies, the question may no longer be simply whether to enter China, but when. As global clinical development becomes more integrated, China may increasingly need to be considered from the beginning of a development strategy rather than treated as a later regional add-on.

I really appreciated Betty’s practical perspective on where the field is heading. These are exactly the types of conversations I hope to explore through Inside China Biotech, a podcast focused on China’s life science innovation and the people building within the ecosystem.

#ChinaBiotech #ClinicalDevelopment #DrugDevelopment #Biotech #ClinicalTrials #MRCT